Literature DB >> 8931663

Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats.

G Pete1, Y Hu, M Walsh, J Sowers, J C Dunbar.   

Abstract

The insulin-like growth factor-I (IGF-I) and its receptors are widely distributed in peripheral vascular tissue, yet their role in the regulation of blood pressure and blood flow remains unknown. This study investigated the effect of IGF-I on blood pressure and selected regional blood flow in normal Wistar rats anesthetized with chloralose/urethane. The femoral artery was cannulated and used to monitor arterial blood pressure. Electromagnetic flow probes were placed around the left common iliac artery, left renal artery, and the superior mesenteric artery, and used to measure blood flow. IGF-I (2.6 micrograms, 5.1 or 10.3 nmol/animal Iv) was injected as a bolus into the femoral vein. Following the injection of IGF-I (10.3 nmol), we observed a significant decrease of plasma glucose (57%) and a significant decrease of mean arterial pressure (MAP) that continued to decline throughout the 60-min experimental period. IGF-I (5.1 nmol) significantly decreased blood glucose by 44% and decreased the MAP by 14% with a nadir at 15 min and recovery after 60 min. A smaller dose of IGF-I (2.6 nmol) did not significantly decrease the blood glucose but resulted in a slight but significant decrease in MAP. The heart rate was increased by 10.3 and 5.1 but not 2.5 nmol of IGF-I. IGF-I (10.3 nmol) was associated with regional vascular responses with a preferential increase in flow of the iliac and superior mesenteric vessels, measured as vascular conductance. IGF-I (5.1 and 2.6 nmol) increased preferentially renal vascular conductance. Preinfusion with L-NAME, a nitric oxide inhibitor, inhibited the effects of IGF-I on flow. We conclude that IGF-I can selectively dilate vascular beds leading to a decrease in blood pressure and that the response to IGF-I is mediated by nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931663     DOI: 10.3181/00379727-213-44049

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  10 in total

Review 1.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 2.  A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I.

Authors:  Klara Sjögren; John-Olov Jansson; Olle G P Isaksson; Claes Ohlsson
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

3.  Estrogens and selective estrogen receptor modulators regulate gene and protein expression in the mesenteric arteries.

Authors:  Connie J Mark-Kappeler; Douglas S Martin; Kathleen M Eyster
Journal:  Vascul Pharmacol       Date:  2011-06-01       Impact factor: 5.773

4.  Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community.

Authors:  Carolyn S P Lam; Ming-Huei Chen; Sean M Lacey; Qiong Yang; Lisa M Sullivan; Vanessa Xanthakis; Radwan Safa; Holly M Smith; Xuyang Peng; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

5.  Cardiovascular action of insulin-like growth factor-1 is not mediated by calcitonin gene-related peptide neurons.

Authors:  Crystal R McRae; Sumangala P Rao; Joseph C Dunbar
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.633

6.  Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction.

Authors:  Km Shioura; Jr Pena; Ph Goldspink
Journal:  Int J Cardiovasc Res       Date:  2014-06-24

7.  Insulin like growth factor-1 (IGF-1) decreases ischemia-reperfusion induced apoptosis and necrosis in diabetic rats.

Authors:  Natalie N Rizk; Javar Myatt-Jones; José Rafols; Joseph C Dunbar
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

8.  Preclinical and clinical evidence of IGF-1 as a prognostic marker and acute intervention with ischemic stroke.

Authors:  Cellas A Hayes; M Noa Valcarcel-Ares; Nicole M Ashpole
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-24       Impact factor: 6.200

Review 9.  Human conditions of insulin-like growth factor-I (IGF-I) deficiency.

Authors:  Juan E Puche; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2012-11-14       Impact factor: 5.531

Review 10.  GH and the cardiovascular system: an update on a topic at heart.

Authors:  Jörgen Isgaard; Michele Arcopinto; Kristjan Karason; Antonio Cittadini
Journal:  Endocrine       Date:  2014-06-28       Impact factor: 3.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.